IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions

Engineered crystallizable fragment (Fc) regions of antibody domains, which assume a unique and unprecedented asymmetric structure within the homodimeric Fc polypeptide, enable completely selective binding to the complement component C1q and activation of complement via the classical pathway without any concomitant engagement of the Fcγ receptor (FcγR). We used the engineered Fc domains to demonstrate in vitro and in mouse models that for therapeutic antibodies, complement-dependent cell-mediated cytotoxicity (CDCC) and complement-dependent cell-mediated phagocytosis (CDCP) by immunological effector molecules mediated the clearance of target cells with kinetics and efficacy comparable to those of the FcγR-dependent effector functions that are much better studied, while they circumvented certain adverse reactions associated with FcγR engagement. Collectively, our data highlight the importance of CDCC and CDCP in monoclonal-antibody function and provide an experimental approach for delineating the effect of complement-dependent effector-cell engagement in various therapeutic settings.

[1]  M. Frank,et al.  Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. , 1972, The Journal of clinical investigation.

[2]  M. Pepys,et al.  Activation of mouse complement by different classes of mouse antibody. , 1979, Immunology.

[3]  M. Neuberger,et al.  Activation of mouse complement by monoclonal mouse antibodies , 1981, European journal of immunology.

[4]  E. Klein,et al.  Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[5]  G. Winter,et al.  The binding site for C1q on IgG , 1988, Nature.

[6]  A. Brünger.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures , 1992, Nature.

[7]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[8]  S. Meri,et al.  Immune evasion of tumor cells using membrane-bound complement regulatory proteins. , 1999, Immunology today.

[9]  Thomas C. Terwilliger,et al.  Electronic Reprint Biological Crystallography Maximum-likelihood Density Modification , 2022 .

[10]  Leonard G. Presta,et al.  Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc , 2000, The Journal of Immunology.

[11]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[12]  R. Huber,et al.  Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. , 2003, Journal of molecular biology.

[13]  Christine Gaboriaud,et al.  The Crystal Structure of the Globular Head of Complement Protein C1q Provides a Basis for Its Versatile Recognition Properties* , 2003, Journal of Biological Chemistry.

[14]  Valeria Grieco,et al.  Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1 , 2003, The Journal of Immunology.

[15]  P. Parren,et al.  Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. , 2004, Blood.

[16]  Michael E. Williams,et al.  Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia1 , 2004, The Journal of Immunology.

[17]  George Georgiou,et al.  Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Parren,et al.  The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201 , 2006, The Journal of Immunology.

[19]  K. Henrick,et al.  Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.

[20]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[21]  P. Parren,et al.  Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX. , 2008 .

[22]  G. Weiner,et al.  NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. , 2008, Blood.

[23]  P. Parren,et al.  Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis1 , 2008, The Journal of Immunology.

[24]  Paul W. H. I. Parren,et al.  Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX1 , 2009, The Journal of Immunology.

[25]  P. Bruhns,et al.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. , 2009, Blood.

[26]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[27]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[28]  John D Lambris,et al.  Complement: a key system for immune surveillance and homeostasis , 2010, Nature Immunology.

[29]  Wen-chao Song,et al.  Complement and its role in innate and adaptive immune responses , 2010, Cell Research.

[30]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[31]  D. Oscier,et al.  Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. , 2011, Blood.

[32]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[33]  J. Leusen,et al.  Mechanisms of action of CD20 antibodies. , 2012, American journal of cancer research.

[34]  M. Zacharias,et al.  Atomic resolution model of the antibody Fc interaction with the complement C1q component. , 2012, Molecular immunology.

[35]  M. Introna,et al.  Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. , 2012, Archives of biochemistry and biophysics.

[36]  S. Jung,et al.  Revisiting the role of glycosylation in the structure of human IgG Fc. , 2012, ACS chemical biology.

[37]  J. Ravetch,et al.  Translating basic mechanisms of IgG effector activity into next generation cancer therapies. , 2012, Cancer immunity.

[38]  P. Bruhns.  Properties of mouse and human IgG receptors and their contribution to disease models. , 2012, Blood.

[39]  A. Lux,et al.  Impact of Immune Complex Size and Glycosylation on IgG Binding to Human FcγRs , 2013, The Journal of Immunology.

[40]  S. Jung,et al.  Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity. , 2013, ACS chemical biology.

[41]  Jason Roszik,et al.  Quantitative high-throughput single-cell cytotoxicity assay for T cells. , 2013, Journal of visualized experiments : JoVE.

[42]  T. Paull,et al.  Proteome-wide detection and quantitative analysis of irreversible cysteine oxidation using long column UPLC-pSRM. , 2013, Journal of proteome research.

[43]  M. Introna,et al.  Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy , 2013, The Journal of Immunology.

[44]  Gary L Gilliland,et al.  An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. , 2014, Methods.

[45]  J. Prestegard,et al.  Immunoglobulin G1 Fc domain motions: implications for Fc engineering. , 2014, Journal of molecular biology.

[46]  C. Liu,et al.  Expression and regulation of complement receptors by human natural killer cells. , 2014, Immunobiology.

[47]  M. Lindorfer,et al.  The role of complement in mAb-based therapies of cancer. , 2014, Methods.

[48]  J. Ravetch,et al.  Type I and type II Fc receptors regulate innate and adaptive immunity , 2014, Nature Immunology.

[49]  Piet Gros,et al.  Complement Is Activated by IgG Hexamers Assembled at the Cell Surface , 2014, Science.

[50]  William J Kelton,et al.  IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions. , 2014, Chemistry & biology.

[51]  Badrinath Roysam,et al.  Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. , 2014, Blood.

[52]  J. Reichert.  Antibody Fc: Linking Adaptive and Innate Immunity , 2014, mAbs.

[53]  K. Honjo,et al.  Emerging roles for the FCRL family members in lymphocyte biology and disease. , 2014, Current topics in microbiology and immunology.

[54]  J. Prestegard,et al.  Role of the hinge and C-gamma-2/C-gamma-3 interface in immunoglobin G1 Fc domain motions: implications for Fc engineering , 2014 .

[55]  Harjeet Singh,et al.  Automated profiling of individual cell-cell interactions from high-throughput time-lapse imaging microscopy in nanowell grids (TIMING) , 2015, Bioinform..

[56]  G Zenke,et al.  Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a. , 2015, Molecular immunology.

[57]  C. Klein,et al.  Activatory and Inhibitory Fcγ Receptors Augment Rituximab-mediated Internalization of CD20 Independent of Signaling via the Cytoplasmic Domain* , 2015, The Journal of Biological Chemistry.

[58]  G. Weiner.  Building better monoclonal antibody-based therapeutics , 2015, Nature Reviews Cancer.

[59]  J. Ravetch,et al.  Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect , 2015, Cell.

[60]  Jinghua Lu,et al.  Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding , 2015, Proceedings of the National Academy of Sciences.

[61]  P. Bruhns,et al.  Mouse and human FcR effector functions , 2015, Immunological reviews.

[62]  C. Hess,et al.  Complement-Mediated Regulation of Metabolism and Basic Cellular Processes. , 2016, Immunity.

[63]  P. Parren,et al.  Monoclonal antibodies targeting CD38 in hematological malignancies and beyond , 2016, Immunological reviews.

[64]  D. Szymkowski,et al.  Harnessing Fc receptor biology in the design of therapeutic antibodies. , 2016, Current opinion in immunology.